Genetic Testing and ATTR-CM: Everything You Need to Know

Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in your family have the condition or are at risk.
Genetic testing can help reduce your risk of such complications, as well as protect your loved ones.
Why Everyone With ATTR-CM Should Be Tested
- Hereditary ATTR-CM runs in families and can cause symptoms around age 30 or later. It leads to amyloid deposits in the heart, nerves, kidneys, and other organs.
- Wild-type ATTR-CM doesn’t run in families and tends to occur in older men. It mostly affects the heart, but it may also cause problems like carpal tunnel syndrome or pain or numbness in the hands or feet.
Why Hereditary ATTR-CM Is Different
There isn’t a cure for ATTR-CM, nor are there treatments to reverse existing amyloid buildup. However, disease-modifying therapies do make it possible to slow the buildup of new amyloid deposits, improving both life expectancy and quality of life in people with hereditary ATTR-CM.
“ATTR-CM is a progressive disorder,” says Dr. Martyn. “The earlier the disease is diagnosed, the better the prognosis, response to therapy, and quality of life patients tend to have.”
- Stabilizer Agents Oral medications like acoramidis (Attruby) and tafamidis (Vyndamax) make it harder for TTR proteins to misfold and create amyloid deposits.
- TTR Silencers Injectable medication vutrisiran (Amvuttra) limits how much TTR the body produces, thereby limiting the production of amyloid deposits.
Hereditary ATTR-CM and Family Risk
If you have a genetic variant of hereditary ATTR-CM but don’t have any signs of the actual condition, you’re considered to be asymptomatic and may develop symptoms later in life. “This person should be followed by their healthcare team with surveillance testing to ensure no symptoms or signs arise in the future,” says James Ampadu, MD, a cardiologist specializing in heart failure with Prisma Health in Columbia, South Carolina.
Does Your Family Need Genetic Testing?
Genetic Counseling: What You Should Know
But the decision to undergo genetic testing can sometimes be stressful. “Genetic testing has implications for the future and can affect family members,” says Quan M. Bui, MD, a cardiologist at UC San Diego Health and assistant professor of medicine at the University of California San Diego School of Medicine.
The Takeaway
- Genetic testing is essential for determining whether a person has the hereditary form of ATTR-CM, which runs in families, or wild type ATTR-CM, which does not, allowing doctors to tailor treatment plans effectively.
- Because ATTR-CM is a progressive disorder with no known cure, early diagnosis with genetic testing allows for the timely use of disease-modifying therapies that help slow protein buildup and improve life expectancy.
- Since first-degree relatives of those with hereditary ATTR-CM have a 50 percent chance of carrying a genetic variant linked to the condition, medical experts recommend that family members undergo testing to identify their risk before severe symptoms develop.
- The testing process is a simple blood or saliva sample that’s often covered by insurance; however, because results can be emotionally difficult to navigate, genetic counselors are available to help families interpret data and plan for long-term monitoring.
Resources We Trust
- Mayo Clinic: Genetic Testing Gives Insight Into Cardiac Conditions
- American Heart Association: Genetic Testing and Counseling for Hereditary Transthyretin Amyloidosis (hATTR)
- Cleveland Clinic: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- Heart Failure Society of America: Like Father, Like Daughter: The Connection Between Genetics and Hereditary ATTR-CM
- Amyloidosis Research Consortium: Hereditary ATTR Amyloidosis
- Transthyretin Amyloidosis (ATTR). Cleveland Clinic. March 2, 2026.
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM). American Heart Association. May 29, 2024.
- Bui QM et al. Patient Perspectives on Genetic Testing in Transthyretin Amyloid Cardiomyopathy: Framing the Conversation to Improve Implementation. Journal of Cardiac Failure – Intersections. September 1, 2025.
- Genetic Testing and Counseling for Hereditary Transthyretin Amyloidosis (hATTR). American Heart Association. May 31, 2024.
- Margolin E et al. Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. Cardiology and Therapy. July 19, 2025.
- Jain A et al. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). StatPearls. April 27, 2023.
- Merino-Merino A et al. Utility of Genetic Testing in Patients With Transthyretin Amyloid Cardiomyopathy: A Brief Review. Biomedicines. December 21, 2023.
- Hereditary ATTR Amyloidosis. Amyloidosis Research Consortium.
- Kittleson MM et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. July 1, 2020.
- Ioannou A et al. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation. November 3, 2022.

Joy Tanaka, PhD
Medical Reviewer
Joy Tanaka, PhD, specializes in clinical molecular genetics. She is dedicated to integrating excellent clinical care with cutting-edge medical research for patients with rare and u...

Marygrace Taylor
Author
Marygrace Taylor is an award-winning freelance health and wellness writer with more than 15 years of experience covering topics including women’s health, nutrition, chronic conditi...